PSA test drives diagnosis within families

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

The brothers of men with prostate cancer face a higher disease risk because of increased diagnostic activity, and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a Swedish study.

The brothers of men with prostate cancer face a higher disease risk because of increased diagnostic activity, and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a Swedish study.

Ola Bratt, MD, and colleagues at Helsingborg Hospital looked at data from the Prostate Cancer Database Sweden and included 22,511 brothers of 13,975 index patients in their analysis.

They found that the incidence of prostate cancer was higher among brothers of prostate cancer patients. Early-stage prostate cancer, found with PSA testing, cropped up most often, according to the study results (J Natl Cancer Inst online, August 19, 2010).

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content